BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zingaropoli MA, Pasculli P, Iannetta M, Perri V, Tartaglia M, Crisafulli SG, Merluzzo C, Baione V, Mazzochi L, Taglietti A, Pauri F, Frontoni M, Altieri M, Gaeta A, Antonelli G, Conte A, Mastroianni CM, Ciardi MR. Infectious risk in multiple sclerosis patients treated with disease-modifying therapies: A three-year observational cohort study. Mult Scler J Exp Transl Clin 2022;8:20552173211065731. [PMID: 35003758 DOI: 10.1177/20552173211065731] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
Number Citing Articles
1 Dominelli F, Zingaropoli MA, Tartaglia M, Tortellini E, Guardiani M, Perri V, Pasculli P, Ciccone F, Malimpensa L, Baione V, Napoli A, Gaeta A, Lichtner M, Conte A, Mastroianni CM, Ciardi MR. Multiple sclerosis-disease modifying therapies affect humoral and T-cell response to mRNA COVID-19 vaccine. Front Immunol 2022;13:1050183. [PMID: 36532061 DOI: 10.3389/fimmu.2022.1050183] [Reference Citation Analysis]
2 . Cladribine/fingolimod/interferon beta. Reactions Weekly 2022;1904:151-151. [DOI: 10.1007/s40278-022-14083-6] [Reference Citation Analysis]